Treatment-resistant depression (TRD) — typically defined as inadequate response to ≥2 adequate antidepressant trials — affects 30% of depressed patients and represents one of the most significant unmet needs in psychiatry. Ketamine's 2019 FDA approval (as intranasal esketamine/Spravato for TRD) and growing off-label IV ketamine use represent the most significant mechanistic advance in antidepressant pharmacology in decades — with a novel mechanism completely distinct from monoamine-targeting antidepressants (SSRIs, SNRIs, TCAs, MAOIs).
Mechanism: Beyond NMDA Antagonism
Ketamine was long classified as an NMDA receptor antagonist (blocking glutamate's principal excitatory receptor) — but the mechanism of its rapid antidepressant effect is more nuanced. The active metabolite (2R,6R)-hydroxynorketamine (HNK) appears critical — it activates AMPA receptors, triggering BDNF release, mTOR pathway activation, and synaptogenesis in prefrontal-limbic circuits that are structurally diminished in depression. This explains ketamine's uniquely rapid onset (hours to days versus weeks for conventional antidepressants) and may explain why the antidepressant effect outlasts the dissociative psychotomimetic effects. The "disinhibition model" is also supported: ketamine blocks NMDA receptors on GABAergic interneurons, releasing cortical glutamate and producing the excitatory burst driving synaptogenesis.
Clinical Evidence: Esketamine and IV Ketamine
Esketamine (Spravato, FDA-approved 2019): five Phase III RCTs demonstrate 50% responder rates in TRD versus 26% placebo (active comparator design with antidepressant background) — meaningful but not dramatic response rates, with rapid onset at 24 hours. SUSTAIN-3 long-term data show 63% relapse-free at 1 year with twice-monthly maintenance. IV racemic ketamine (off-label): typically 0.5 mg/kg IV over 40 minutes, 2–3× weekly for 2–3 weeks induction. Meta-analyses show ~60% response rates in TRD — superior to oral antidepressants but requiring IV administration in monitored settings. Key risks: dissociative symptoms during infusion (managed with benzodiazepines if needed), cardiovascular stimulation (BP monitoring required), addiction potential in vulnerable patients (ketamine is a Schedule III substance). Contraindications: uncontrolled hypertension, history of psychosis or ketamine abuse. For healthcare facilities providing psychiatric services and ketamine clinic infrastructure, our vascular access catalog includes IV supplies for infusion protocols, and our diagnostic equipment section includes monitoring equipment for ketamine administration settings.
